ObesityNovo Nordisk invests €2.1bn in production expansionLatest NewsIn the race for global market share of its obesity and diabetes blockbuster semaglutide, Novo Nordisk is expanding production in Europe. Read more 24 November 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/Novo_Chartes.jpg 598 896 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-11-24 09:07:572024-07-09 12:50:26Novo Nordisk invests €2.1bn in production expansion